Efficacy and safety of a new leuprolide acetate [leuprorelin] 17 mg depot formulation, GP-Pharm S.A., when given as palliative treatment to prostate cancer patients.

Trial Profile

Efficacy and safety of a new leuprolide acetate [leuprorelin] 17 mg depot formulation, GP-Pharm S.A., when given as palliative treatment to prostate cancer patients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2010

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Oct 2008 Status changed from recruiting to as active, no longer recruiting reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top